Noncompetitive functional inhibition at diverse, human nicotinic acetylcholine receptor subtypes by bupropion, phencyclidine, and ibogaine

Journal of Pharmacology and Experimental Therapeutics

Volumn 288, Issue 1, 1999, Pages 88-92

  Fryer, John D ^a   Lukas, Ronald J ^a  

^a BARROW NEUROLOGICAL INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMFEBUTAMONE; CARBACHOL; IBOGAINE; NICOTINIC RECEPTOR; NICOTINIC RECEPTOR BLOCKING AGENT; PHENCYCLIDINE; RECEPTOR SUBTYPE; RUBIDIUM 86;

ARTICLE; CHOLINERGIC SYSTEM; COMPETITIVE INHIBITION; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG DEPENDENCE TREATMENT; HUMAN; HUMAN CELL; NEUROBLASTOMA CELL; NEUROPHARMACOLOGY; NEUROTRANSMISSION; PRIORITY JOURNAL;

ANTIDEPRESSIVE AGENTS; BUPROPION; CELL LINE; DOPAMINE UPTAKE INHIBITORS; EXCITATORY AMINO ACID ANTAGONISTS; HUMANS; IBOGAINE; PHENCYCLIDINE; RECEPTORS, NICOTINIC; TUMOR CELLS, CULTURED;

EID: 0032934644     PISSN: 00223565     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (27)

1. Albuquerque EX, Tsai MC, Aronstam RS, Eldefrawi AT and Eldefrawi ME (1980) Sites of action of phencyclidine. II. Interaction with the ionic channel of the nicotinic receptor. Mol Pharmacol 18:167-178.
2. Ascher J, Cole J, Colin J-N, Feighner JP, Ferris RM, Fibiger HC, Golden RN, Martin P, Potter WZ, Richelson E and Fridolin S (1995) Bupropion: A review of its mechanism of antidepressant activity. J Clin Psychiatry 56:395-401.
3. Badio B, Padgett W and Daly J (1997) Ibogaine: A potent noncompetitive blocker of ganglionic/neuronal nicotinic receptors. Mol Pharmacol 51:1-5.
4. Bencherif M, Eisenhour CM, Prince R J, Lippiello PM and Lukas RJ (1995) The "calcium antagonist" TMB-8 (3,4,5-timethoxy benzole acid 8-(diethylamino)octyl ester] is a potent, non-competitive, functional antagonist at diverse nicotinic acetylcholine receptor subtypes. J Pharmacol Exp Ther 275:1418-1426.
5. Conroy W and Berg D (1995) Neurons can maintain multiple classes of nicotinic acetylcholine receptors distinguished by different subunit compositions. J Biol Chem 270:4424-4431.
6. Donaldson JO and Baselt RC (1979) CSF phencyclidine. Am J Psychiatry 136(10): 1341-1342.
7. Galzi J-L and Changeux J-P (1994) Ligand-gated ion channels as unconventional allosteric proteins. Curr Opin Struct Biol 4:554-565.
8. Golden RN, De Vane CL, Laizure SC, Rudorfer MV, Sherer MA and Potter WZ (1988) Bupropion in depression. II. The role of metabolites in clinical outcome. Arch Gen Psychiatry 45:145-149.
9. Halberstadt AL (1995) The phencyclidine-glutamate model of schizophrenia. Clin Neruopharmacol 18:237-249.
10. Hough LB, Pearl SM, and Glick SD (1996) Tissue distribution of ibogaine after intraperitoneal and subcutaneous administration. Life Sci 58:PL119-PL122.
11. Hsyu PH, Singh A, Giargiari TD, Dunn JA, Ascher JA, and Johnston JA (1997) Pharmacokinetics of bupropion and its metabolites in cigarette smokers versus nonsmokers. J Clin Pharmacol 37:737-743.
12. Hurt RD, Sachs DP, Glover ED, Offord KP, Johnston JA, Dale LC, Khayrallah MA, Schroeder DR, Glover PN, Sullivan CR, Croghan IT, and Sullivan PM (1997) A comparison of sustained-release bupropion and placebo for smoking cessation. N Engl J Med 337:1195-202.
13. Kloog Y, Gabrialevitz A, Kalir A, Balderman D, and Sokolovsky M (1979) Functional evidence for a second binding site of nicotinic antagonists using phencyclidine derivatives. Biochem Pharmacol 28:1447-1450.
14. Lindstrom J (1996) Neuronal nicotinic acetylcholine receptors, in Ion Channels (Narahashi T ed), vol 4, pp 377-450, Plenum Press, New York.
15. Lukas RJ (1986) Characterization of curarimimetic neurotoxin binding sites on membrane fractions derived from the human medulloblastoma clonal line. TE671. J Neurochem 46:1936-1941.
16. Lukas RJ (1989) Pharmacological distinctions between functional nicotinic acetylcholine receptors on the PC12 rat pheochromocytoma and the TE671 human medulloblastoma. J Pharmacol Exp Ther 251:175-182.
17. Lukas RJ and Bencherif M (1992) Heterogeneity and regulation of nicotinic acetylcholine receptors. Int Rev Neurobiol 34:25-131.
18. Lukas RJ, Norman SA and Lucero L (1993) Characterization of nicotinic acetylcholine receptors expressed by cells of the SH-SY5Y human neuroblastoma clonal line. Mol Cell Neurosci 4:1-12.
19. Lukas RJ (1998) Neuronal nicotinic acetylcholine receptors, in The Nicotinic Acetylcholine Receptor: Current Views and Future Trends (Barrantes FJ ed) pp 145-173, Landes Bioscience, Springer Verlag, Heidelberg/Berlin and Georgetown, TX.
20. Marwah J, and Pitts DK (1986) Psychopharmacology of phencyclidine. NIDA 64: 127-133.
21. Popik P, Layer RT and Skolnick P (1995) 100 years of ibogaine: Neurochemical and pharmacological actions of a putative anti-addictive drug. Pharmacol Rev 47:235-253.
22. Puchacz E, Buisson B. Bertrand D and Lukas RJ (1994) Functional expression of nicotinic acetylcholine receptors containing rat α7 subunits in human neuroblastoma cells. FEBS Lett 354:155-159.
23. Rose JE, Behm FM, Westman EC, Levin ED, Stein RM and Ripka GV (1994) Mecamylamine combined with nicotine skin patch facilitates smoking cessation beyond nicotine patch treatment alone. Clin Pharmacol Ther 56(1):86-99.
24. Schneider AS. Nagel JE and Mah SJ (1996) Ibogaine selectively inhibits nicotinic receptor-mediated catecholamine release. Eur J Pharmacol 317:R1-R2
25. Suckow RF, Smith TM, Perumal AS and Cooper TB (1986) Pharmacokinetics of bupropion and metabolites in plasma and brain of rats, mice, and guinea pigs. Drug Metab Dispos 14:692-697.
26. Thornberg SA and Saklad SR (1996) A review of NMDA receptors and the phencyclidine model of schizophrenia. Pharmacotherapy 16:82-93.
27. Yamamoto H, Sagi N, Yamamoto T, Goji Y, Okuwa M, Yoshii M, and Moroji T (1992) Inhibitory effects of psychotomimetic σ ligands on nicotine-induced K+ flux from differentiated PC12 cells. Neurosci Lett 147:97-100.